Prelude Therapeutics Narrows Q1 Loss, Secures $90M to Extend Cash Runway to Q2 2028
Summary
Prelude Therapeutics reported a narrower Q1 net loss of $10.39 million, or $0.13 per share, driven by a significant reduction in operating expenses to $18.76 million. This decline was primarily due to lower R&D costs following the strategic decision to pause SMARCA2 clinical trials. Crucially, the company announced a $90 million offering, which has extended its cash runway into the second quarter of 2028. This is a material improvement from the Q2 2027 cash runway previously outlined in its March 10, 2026 10-K filing, providing a longer financial cushion for its operations. Looking ahead, Prelude expects to file an Investigational New Drug (IND) application for its KAT6A degrader PRT13722 by mid-2026, representing a key pipeline catalyst.
At the time of this announcement, PRLD was trading at $4.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $302.4M. The 52-week trading range was $0.75 to $5.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.